

Optimizing Hemoglobin Levels and Beyond: Strength for Living and Meaningful Survival?

**The 3rd Educational
Symposium on
Advances In Cancer
Anemia Management**

**20-23 March 2003
Vienna, Austria**



VIENNA

**Focus on Hematologic
Malignancies: The Connection
Between Anemia, Fatigue, and
Quality of Life**



ANEMIA

Focus on Hematologic Malignancies

- Prevalence of anemia among patients with hematologic malignancies
- Correlation between fatigue and hemoglobin (Hb) levels
- Recognition of Hb levels and anemia as prognostic indicators for survival
- Improvement of hematologic and quality of life (QOL) parameters with recombinant human erythropoietin (rHuEpo, epoetin alfa)
- Potential for epoetin alfa to downstage disease
- Data suggesting that epoetin alfa may offer antineoplastic benefits in addition to its red blood cell stimulating activity

Contents

ECAS Reveals High Prevalence of Anemia in Patients with Hematologic Malignancies

Heinz Ludwig, M.D., Vienna, Austria

Correlation Between Fatigue and Hb Level in Multiple Myeloma Patients: Results of a Cross-Sectional Study

Mario Boccadoro, M.D., Torino, Italy

Anemia has a Prognostic and Clinical Impact in Hematologic Malignancies

Joan Bladé, M.D., Barcelona, Spain

Downstaging Rai Stage III B-Chronic Lymphocytic Leukemia Patients: Clinical Evidence

Gerassimos Pangalis, M.D., Athens, Greece

Epoetin Alfa Induces Tumor Regression and Antitumor Immune Responses in Myeloma Patients and in a Murine Myeloma Model

Moshe Mittelman, M.D., Tel-Aviv, Israel

Role of Epoetin Alfa in Managing Anemia in Patients with HM

Timothy Littlewood, M.D., Oxford, England